{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ulcerative-colitis/management/fertility-pregnancy-breastfeeding-with-ulcerative-colitis/","result":{"pageContext":{"chapter":{"id":"56868b16-5233-5bb8-9412-d2d9bfafe8d9","slug":"fertility-pregnancy-breastfeeding-with-ulcerative-colitis","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis","depth":2,"htmlHeader":"<!-- begin field 36eb9427-991a-435e-bc0b-0c7a3467e5e8 --><h2>Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis</h2><!-- end field 36eb9427-991a-435e-bc0b-0c7a3467e5e8 -->","summary":"Covers advice on fertility, and management of ulcerative colitis in pregnancy and breastfeeding.","htmlStringContent":"<!-- begin item af8b7871-cbe8-4b40-8430-4c43bf27efb2 --><!-- begin field a0368aca-acdd-42e4-b427-acbd0087ce74 --><p>From age 13 years onwards (Female).</p><!-- end field a0368aca-acdd-42e4-b427-acbd0087ce74 --><!-- end item af8b7871-cbe8-4b40-8430-4c43bf27efb2 -->","topic":{"id":"34aee656-b482-5065-8656-44c487e4e347","topicId":"6a63bd87-53c1-487d-8426-773cffdb4c43","topicName":"Ulcerative colitis","slug":"ulcerative-colitis","lastRevised":"Last revised in April 2020","chapters":[{"id":"8ec19c69-a796-514b-a267-91bd57a12fe3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dc4de3c1-9955-536e-9789-a900261d2189","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"04875f8c-29b3-5d60-8e5c-06930138cfc4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04f00df3-2de5-5c61-bb95-25edda5f885b","slug":"changes","fullItemName":"Changes"},{"id":"12402ddb-2eb9-589e-a1c3-24d50e2538f8","slug":"update","fullItemName":"Update"}]},{"id":"2c186889-f3c1-5094-b0ce-0b9a81f46d61","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"36a3da73-b00f-5ee2-bfd9-33293a674904","slug":"goals","fullItemName":"Goals"},{"id":"5c86e0bc-3476-59dd-b120-519602968645","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3ab8e65e-aac9-54a1-abb3-9185c76c6004","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0efa89a1-51f7-59ff-95ce-94faac48f8a5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a2b17331-6cfc-56eb-84c5-433f78f4364c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"01a70081-193a-5d75-92fb-45f84ee7b317","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"87cfff6e-6028-5fda-aee6-4473268cac77","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"116a07eb-6832-5d49-aa1d-497f7c0684a9","slug":"definition","fullItemName":"Definition"},{"id":"fef2143b-1809-58f3-bdf9-0d73710d89ae","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9c9a2e21-7e98-5876-945d-ec18ebfaee62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5102ad12-cd60-5939-ad9a-00d4dafca9b0","slug":"complications","fullItemName":"Complications"},{"id":"488ac85b-91d2-5298-9127-69ae212ceeac","slug":"extra-intestinal-manifestations","fullItemName":"Extra-intestinal manifestations"},{"id":"9ff94ba6-78d6-5ed0-9cda-f234b24236d7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2149059a-c90f-50e5-9fa2-227a488d2004","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"40b81845-1ebc-55b2-b825-05a3d62e3cc4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"0102b680-c790-5c87-aaec-ea332f5fc9b2","slug":"investigations","fullItemName":"Investigations"},{"id":"2ea841c6-272f-5b4b-a165-499ec0228439","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"468c6dcc-e9f2-5154-9f2b-30d7dafb7415","fullItemName":"Management","slug":"management","subChapters":[{"id":"6a9b8b90-a418-5e1b-9442-ac55ee36430f","slug":"suspected-ulcerative-colitis","fullItemName":"Scenario: Suspected ulcerative colitis"},{"id":"6d8002d3-29fe-5bfd-ba03-7ce0173636e4","slug":"confirmed-ulcerative-colitis","fullItemName":"Scenario: Confirmed ulcerative colitis"},{"id":"56868b16-5233-5bb8-9412-d2d9bfafe8d9","slug":"fertility-pregnancy-breastfeeding-with-ulcerative-colitis","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis"},{"id":"7708c2de-0c02-5b83-a354-70788b3dc297","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"010b277d-6575-5cdc-b995-6fc7d89fb745","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a8ed7157-985a-58a5-b567-571fa748a73b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1164542-c6ec-5b63-bfee-efc59657c778","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"568370d3-2e5b-55a4-ae50-2eeeb5ca3234","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"df1aecf8-eeb0-5069-965e-21ccf0690af8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"889198a1-b809-54b2-b803-3ee02e6f45af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a290d39a-e351-5dec-9607-943a59e60b2e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"916d81a4-ae1e-529e-936f-183b4514ba9f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"468c6dcc-e9f2-5154-9f2b-30d7dafb7415","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e35cd875-2000-5feb-8cbe-858b0e618a67","slug":"fertility-advice","fullItemName":"Fertility advice","depth":3,"htmlHeader":"<!-- begin field 1131fb2a-23c4-47a0-8054-a74a847e2a5c --><h3>What should I advise about fertility issues?</h3><!-- end field 1131fb2a-23c4-47a0-8054-a74a847e2a5c -->","summary":null,"htmlStringContent":"<!-- begin item f38d682f-20a2-40d0-b92e-4f423b1f41fb --><!-- begin field 667b6d98-c99a-4657-b131-9f26c8210111 --><h4>Contraception advice</h4><ul><li>For women with ulcerative colitis, the choice of contraceptive method may be influenced by factors such as malabsorption, surgical history, prolonged immobility, extra-intestinal manifestations such as primary sclerosing cholangitis, and associated conditions such as osteoporosis and venous thromboembolism.<ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for detailed information on contraception options for women with different co-morbidities.</li><li>See the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <a data-hyperlink-id=\"6d5909e0-587f-47b8-8ed6-aa3e008c46c9\" href=\"https://www.fsrh.org/standards-and-guidance/documents/ukmec-2016/\" target=\"_blank\">UK Medical Eligibility Criteria for Contraceptive Use (UKMEC)</a> for detailed information on prescribing contraception for people with inflammatory bowel disease.<ul><li>Oral methods may be less reliable if there is significant malabsorption or history of small bowel resection. Oral methods are unaffected by colectomy and ileostomy.</li></ul></li><li>Ensure that effective contraception is prescribed during treatment and for at least:<ul><li>Three months after treatment with methotrexate or mercaptopurine (if taken by either partner).</li><li>Six months after treatment with anti-tumour necrosis factor (TNF)-alpha monoclonal antibody agents (such as infliximab or adalimumab).</li></ul></li></ul></li><li>Offer sources of support and information, such as the Crohn's and Colitis UK patient information leaflet <a data-hyperlink-id=\"c49092bc-5930-4ea8-be25-a993004ed5e6\" href=\"http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/sexual-relationships-and-IBD\" target=\"_blank\">Sexual relationships and IBD</a>.</li></ul><h4>Fertility advice</h4><ul><li>Advise women with ulcerative colitis that:<ul><li>There is no evidence that inactive or active disease affects fertility.</li><li>Those who have a history of abdominal or pelvic sepsis, surgery, or adhesions, may be at increased risk of impaired tubal function.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/infertility/\">Infertility</a> for more information.</li></ul></li><li>Advise men with ulcerative colitis that:<ul><li>Fertility is unlikely to be affected for most men, however a history of pelvic surgery may lead to erectile dysfunction or ejaculatory problems. In addition, men who undergo ileo-anal pouch surgery may develop retrograde ejaculation and erectile dysfunction. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a> for more information.</li><li>Drug treatment with sulfasalazine or methotrexate may cause reversible oligospermia. Infliximab treatment may affect semen quality by reducing motility in some men.</li></ul></li><li>Offer sources of support and information, such as the Crohn's and Colitis UK patient information leaflet <a data-hyperlink-id=\"6cf8dd49-e441-4c63-9aae-aa3e009b70ae\" href=\"http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/Reproductive_Health.pdf\" target=\"_blank\">Reproductive health and IBD</a>.</li></ul><h4>Pre-pregnancy planning</h4><ul><li>Refer women and men with ulcerative colitis to a gastroenterologist for pre-pregnancy counselling <em>before</em> trying to conceive, if they are planning a pregnancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> for more information.<ul><li>For women, specialist drug treatment may need to be changed, as some medications are teratogenic. Ulcerative colitis management should be optimized by the specialist, to ensure that the disease is well controlled and in remission before trying to conceive. This reduces the risk of persistent disease activity and relapse during pregnancy.</li><li>For men, drug treatments that affect spermatogenesis may need to be changed to a different drug or temporarily stopped, following specialist assessment.</li></ul></li></ul><!-- end field 667b6d98-c99a-4657-b131-9f26c8210111 --><!-- end item f38d682f-20a2-40d0-b92e-4f423b1f41fb -->","subChapters":[{"id":"262542e5-b2d4-520c-b71a-2922afa10a10","slug":"basis-for-recommendation-c16","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 886b655b-8e6d-429f-b316-b02f3ca50c73 --><h4>Basis for recommendation</h4><!-- end field 886b655b-8e6d-429f-b316-b02f3ca50c73 -->","summary":null,"htmlStringContent":"<!-- begin item c163e3f3-c3e2-4b36-ace3-e1b6c473da84 --><!-- begin field f668a4a4-3d1b-4126-af4f-8abf66fa066c --><p>The recommendations on contraception, fertility, and pre-pregnancy planning are based on the European Crohn's and Colitis Organisation (ECCO) consensus guideline <em>The second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>], the Faculty of Sexual and Reproductive Healthcare (FSRH) guidelines <em>Sexual and reproductive health for individuals with inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>] and <em>UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2016)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016b</a>], the British Society of Gastroenterology (BSG) <em>Guidelines on the management of inflammatory bowel disease in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Mowat et al, 2011</a>], and expert opinion in a review article on ulcerative colitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Ford, 2013</a>].</p><h5>Advice on contraception issues</h5><ul><li>The information on factors affecting choice of contraceptive method, and the safety and efficacy of oral methods, is based on the FSRH UKMEC document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016b</a>].</li><li>The recommendations on the requirements for effective contraception when and after taking certain specialist drug treatments are based on the FSRH guideline on inflammatory bowel disease (IBD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].</li></ul><h5>Advice on fertility issues</h5><ul><li>The information on the potential impact of pelvic or abdominal sepsis or surgery on fertility is based on the ECCO consensus guideline on reproduction and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>] and the FSRH guideline on IBD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].<ul><li>The FSRH guideline notes that for women following pelvic surgery, such as a proctocolectomy or an ileal pouch-anal anastomosis (IPAA), the risk of subfertility may increase as much as three-fold.</li></ul></li><li>The information on the effects of sulfasalazine, methotrexate, and infliximab on male spermatogenesis and semen motility is based on the ECCO consensus guideline on reproduction and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>] and the FSRH guideline on IBD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].</li></ul><h5>Advice on pre-pregnancy planning</h5><ul><li>The ECCO consensus guideline on reproduction and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>] and the FSRH guideline on IBD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>] recommend that appropriate referral for pre-pregnancy and pre-conception counselling should be available for men and women with inflammatory bowel disease, to advise and optimize disease management before conception.<ul><li>Optimum disease control is needed prior to conception and during pregnancy, as if conception occurs during active ulcerative colitis, there is an increased risk of persistent disease activity or relapse during pregnancy, and an increased risk of adverse pregnancy outcomes, such as miscarriage, preterm labour, and low birth-weight [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Mowat et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Ford, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>]. If conception occurs at a time of quiescent disease, the risk of relapse is the same as in non-pregnant women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>].</li><li>The rate of voluntary childlessness is higher among women with ulcerative colitis than the general population. This may be due to concerns about the risk of adverse pregnancy outcomes, possible teratogenicity of drug treatments, and the heritability of the disease. Pre-pregnancy counselling may provide an opportunity for women to identify and discuss these issues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].</li></ul></li><li>The FSRH guideline on IBD notes that the decision to discontinue any treatment requires expert clinical judgement, balancing the risks of stopping the drug against the risks associated with continuing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].</li></ul><!-- end field f668a4a4-3d1b-4126-af4f-8abf66fa066c --><!-- end item c163e3f3-c3e2-4b36-ace3-e1b6c473da84 -->","subChapters":[]}]},{"id":"8cc589a5-5df6-5914-872b-eda0d6058046","slug":"pregnancy-breastfeeding-advice","fullItemName":"Pregnancy and breastfeeding advice","depth":3,"htmlHeader":"<!-- begin field 209ec8c1-b256-48e9-a970-f07baba8edb6 --><h3>What should I advise about pregnancy and breastfeeding?</h3><!-- end field 209ec8c1-b256-48e9-a970-f07baba8edb6 -->","summary":null,"htmlStringContent":"<!-- begin item 09a8f930-dc00-4496-98e1-951e0bf2cdcf --><!-- begin field 59618f01-ca3b-4b61-bc0f-9faee4e93596 --><p><strong>Advise women and men they need to be referred to a gastroenterologist <em>before</em> trying to conceive if they are <a class=\"topic-reference internal-reference\" href=\"/topics/ulcerative-colitis/management/fertility-pregnancy-breastfeeding-with-ulcerative-colitis/#fertility-advice\">planning a pregnancy</a>. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> for more information.</strong></p><h4>Pregnancy advice</h4><ul><li>If a woman has a planned pregnancy, ensure she is jointly managed by a gastroenterologist and obstetrician with appropriate expertise.</li><li>If a woman has an unplanned pregnancy and she or her partner is prescribed:<ul><li>Methotrexate, mercaptopurine, infliximab, or adalimumab, seek immediate specialist advice from a gastroenterologist and/or a specialist in fetal medicine about stopping and changing treatment, and starting folic acid supplementation. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/ulcerative-colitis/management/fertility-pregnancy-breastfeeding-with-ulcerative-colitis/#fertility-advice\">Fertility issues</a> for more information.</li><li>Other medication, advise the woman to continue maintenance drug treatment, start folic acid supplementation, and arrange an urgent specialist gastroenterology review appointment to ensure that management of ulcerative colitis is optimized.</li></ul></li><li>Advise that if a woman has had significant pelvic surgery or active rectal involvement, she may be offered elective Caesarean section to reduce the risk of potential anal sphincter damage.</li><li>Offer sources of support and information, such as the Crohn's and Colitis UK patient information leaflet <a data-hyperlink-id=\"75ea3749-dec3-4ec5-a78e-aa3e00a97645\" href=\"http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/Pregnancy_and_IBD\" target=\"_blank\">Pregnancy and IBD</a>.</li></ul><h4>Breastfeeding advice</h4><ul><li>If a woman with ulcerative colitis wishes to breastfeed, seek specialist gastroenterology advice if there is any uncertainty about the safety of breastfeeding while taking specialist medication.</li><li>If a woman experiences problems breastfeeding, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/breastfeeding-problems/\">Breastfeeding problems</a> and <a class=\"topic-reference external-reference\" href=\"/topics/mastitis-breast-abscess/\">Mastitis and breast abscess</a> for more information.</li><li>Advise women that the risk of a <a class=\"topic-reference internal-reference\" href=\"/topics/ulcerative-colitis/management/confirmed-ulcerative-colitis/#management-of-a-flare-up\">flare-up</a> of disease may be increased post-partum.</li></ul><!-- end field 59618f01-ca3b-4b61-bc0f-9faee4e93596 --><!-- end item 09a8f930-dc00-4496-98e1-951e0bf2cdcf -->","subChapters":[{"id":"7e176d2d-b587-52d0-b68a-640fb948222f","slug":"basis-for-recommendation-29d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1b7358a0-8163-4828-9068-470884801429 --><h4>Basis for recommendation</h4><!-- end field 1b7358a0-8163-4828-9068-470884801429 -->","summary":null,"htmlStringContent":"<!-- begin item 29df278f-b1a2-47f7-ad40-483115c2eb24 --><!-- begin field a42fd1f8-b943-4752-bdbf-f8ad186b89c2 --><p>The recommendations on pregnancy and breastfeeding are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Ulcerative Colitis: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">NICE, 2019</a>], the European Crohn's and Colitis Organisation (ECCO) consensus guideline <em>The second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>], the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Sexual and reproductive health for individuals with inflammatory bowel disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>], the British Society of Gastroenterology (BSG) <em>Guidelines on the management of inflammatory bowel disease in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Mowat et al, 2011</a>], and expert opinion in a review article on ulcerative colitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Ford, 2013</a>].</p><h5>Advice on pregnancy issues</h5><ul><li>The recommendation to ensure that women who are pregnant are jointly managed by a gastroenterologist and obstetrician is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">NICE, 2019</a>], the FSRH guideline on inflammatory bowel disease (IBD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>], and the BSG guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Mowat et al, 2011</a>]. It is also extrapolated from the ECCO consensus guideline on reproduction and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>].<ul><li>The NICE clinical guideline recommends effective communication and information-sharing across specialities, including obstetrics and gynaecology, gastroenterology, and primary care. This involves giving specialist information on the risks and benefits of drug treatments to induce or maintain remission during pregnancy.</li><li>Optimum disease control is needed during pregnancy, as persistent disease activity or relapse during pregnancy may be associated with an increased risk of adverse pregnancy outcomes, such as miscarriage, preterm labour, and low birth-weight [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Mowat et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>]. The FSRH guideline on IBD notes that the benefits of clinical remission in pregnancy generally outweigh the risks to the fetus from specialist medication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>]. This is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Ford, 2013</a>].</li></ul></li><li>The recommendation to seek immediate specialist advice if a woman or her partner is taking potentially teratogenic medication is based on the FSRH guideline on IBD, which notes that the decision to discontinue any treatment requires expert clinical judgement, balancing the risks of stopping the drug against the risks associated with continuing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].</li><li>The ECCO consensus guideline notes that adherence to planned maintenance treatment will reduce the risk of relapse in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>].</li><li>The information that a woman may be offered an elective Caesarean section in certain clinical situations is based on the FSRH guideline on IBD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>], the ECCO consensus guideline on reproduction and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>], and the BSG guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Mowat et al, 2011</a>]. Expert opinion in a review article states that one in five pregnant women with ulcerative colitis will have a Caesarean section [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">Ford, 2013</a>].</li></ul><h5>Advice on breastfeeding issues</h5><ul><li><p>The recommendations on breastfeeding are based on the FSRH guideline on IBD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>], the ECCO consensus guideline on reproduction and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">van der Woude et al, 2015</a>], and are pragmatic, based on what CKS considers to be good clinical practice. </p><ul><li>The decision to discontinue any treatment requires expert clinical judgement, balancing the risks of stopping the drug against the risks associated with continuing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ulcerative-colitis/references/\">FSRH, 2016a</a>].</li><li>The ECCO consensus guideline notes that in women with ulcerative colitis, the risk of a post-partum flare may be increased.</li></ul></li></ul><!-- end field a42fd1f8-b943-4752-bdbf-f8ad186b89c2 --><!-- end item 29df278f-b1a2-47f7-ad40-483115c2eb24 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}